Literature DB >> 2027749

Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1.

K Rittner1, G Sczakiel.   

Abstract

Antisense RNA, transcribed intracellularly from constitutive expression cassettes, inhibits the replication of the human immunodeficiency virus type 1 (HIV-1) as demonstrated by a quantitative microinjection assay in human SW480 cells. Infectious proviral HIV-1 DNA was co-microinjected together with a fivefold molar excess of plasmids expressing antisense RNA complementary to a set of ten different HIV-1 target regions. The most inhibitory antisense RNA expression plasmids were targeted against a 1 kb region within the gag open reading frame and against a 562 base region containing the coding sequences for the regulatory viral proteins tat and rev. Experimental evidence is presented that the antisense principle is the inhibitory mechanism in this assay system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2027749      PMCID: PMC333895          DOI: 10.1093/nar/19.7.1421

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  50 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Antisense RNA inhibition of endogenous genes.

Authors:  J T Stout; C T Caskey
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 3.  Rapid evolution of RNA viruses.

Authors:  D A Steinhauer; J J Holland
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

4.  Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives.

Authors:  S Shibahara; S Mukai; H Morisawa; H Nakashima; S Kobayashi; N Yamamoto
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus.

Authors:  A D Friedman; S J Triezenberg; S L McKnight
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

8.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

Authors:  G Sczakiel; M Pawlita
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.

Authors:  S Agrawal; T Ikeuchi; D Sun; P S Sarin; A Konopka; J Maizel; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  17 in total

1.  Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.

Authors:  M Homann; M Tabler; S Tzortzakaki; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P.

Authors:  D Plehn-Dujowich; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 4.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner.

Authors:  H Wodrich; A Schambach; H G Kräusslich
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

6.  Theoretical design of antisense genes with statistically increased efficacy.

Authors:  M J Lehmann; V Patzel; G Sczakiel
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

7.  A new RNA element located in the coding region of a murine endogenous retrovirus can functionally replace the Rev/Rev-responsive element system in human immunodeficiency virus type 1 Gag expression.

Authors:  H Wodrich; J Bohne; E Gumz; R Welker; H G Kräusslich
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells.

Authors:  M O Westendorp; M Li-Weber; R W Frank; P H Krammer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1.

Authors:  K Rittner; C Burmester; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

10.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.